منذ 16سا
S&P 500 Faces 2% Futures Drop as Brent Oil Jumps Toward $83 and Hormuz Risks Mount
The S&P 500's 2026 rally is under pressure as futures fell about 2% in early Tuesday trading while Brent crude briefly pushed toward 83 USD and tensions around the Strait of Hormuz intensified. The index had already slipped 0.5% to 6,860.71 on Monday as oil prices jumped more than 6% and volatility surged, forcing investors to reassess inflation, Federal Reserve expectations and sector positioning.
منذ 16سا
2-19
Bitcoin Holds Near $66,900 as Goldman Sachs CEO Reveals Personal BTC Position and Liquidations Mount
Bitcoin is trading close to $66,900 within a 24‑hour band of about $65,800 to $68,400, while derivatives markets show heavy long liquidations near the $66,000 support zone. At the World Liberty Financial Forum in Mar‑a‑Lago, Goldman Sachs CEO David Solomon disclosed he holds a small amount of Bitcoin, as attendees also highlighted a tokenized real‑estate loan deal for a Maldives resort tied to World Liberty Financial and Securitize.
BTC
BTC+0.26%
2-19
2-15
Bitcoin Trades Near $70,500 on February 15, 2026 as ETFs See $15.1M Inflows and Whales Accumulate
On February 15, 2026, Bitcoin is trading around $70,500 after bouncing from an early‑February slide toward 60k, restoring its market capitalization to about $1.4 trillion. Around $189 million in futures positions were liquidated over a recent 24‑hour span as derivatives leverage reset, while U.S. spot Bitcoin ETFs recorded roughly $15.1 million of net inflows on February 14. Large wallets holding more than 1,000 BTC reportedly added about 53,000 BTC during the sell‑off, and traders are now watching support near $60,000-$61,000 and resistance above $72,000 toward $75,000.
المختارة
BTC
BTC+0.26%
2-15
2-10
CSL Shares Slide 5% to A$171 Ahead of FY26 Half-Year Results on Earnings Risk
CSL Ltd shares fell 5% in early trade to A$171.39, extending a multi‑year drawdown of 39% from early 2025 highs as traders position for half‑year FY26 earnings. The A$150B plasma and vaccine group faces concerns over potential revenue and EPS shortfalls, weaker US flu vaccine demand and reimbursement issues for new immunoglobulin products, while options and volume data point to expectations of further downside.
2-10